Evidence map›Paper›PMID 40522586›Full record

ArticleHealth economics review2025

Economic burden of end stage renal disease: a case study in southern Iran.

Habib Omranikhoo, Saeed Shabani, Atefeh Esfandiari, Hedayat Salari, Mehdi Rezaee

Abstract read
In one paragraph

Article in Health economics review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Habib OmranikhooDepartment of Management, Economics and Health policy, School of Health, Bushehr University of Medical Sciences, Bushehr, Iran.
Saeed ShabaniSchool of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Atefeh EsfandiariDepartment of Management, Economics and Health policy, School of Health, Bushehr University of Medical Sciences, Bushehr, Iran.
Hedayat SalariDepartment of Management, Economics and Health policy, School of Health, Bushehr University of Medical Sciences, Bushehr, Iran.
Mehdi RezaeeDepartment of Management, Economics and Health policy, School of Health, Bushehr University of Medical Sciences, Bushehr, Iran. m.rezaee8666@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe condition of renal failure is widely regarded as one of the most significant challenges currently facing public health and typically treated through hemodialysis. The objective of this study was to estimate the Economic burden of hemodialysis in Bushehr province and, by extension, Iran.

methodThis was a cross-sectional and partial economic evaluation study conducted to estimate the Economic burden of hemodialysis using the bottom-up approach in Bushehr province and, consequently Iran. Direct medical costs and the number of hemodialysis patients were attained from health information system (HIS). Indirect costs were calculated by including the cost of lost production due to hospitalization, rest at home, absenteeism from work, and also the loss of productivity due to premature death. finally, to reduce the uncertainty around the data, a two-way sensitivity analysis was carried out.

resultThe mean cost of hemodialysis per patient was calculated to be 169,016 $ Purchasing Power Parity (PPP) resulting in a total economic burden of hemodialysis for Bushehr province and Iran in 2022 as 13,849,321 and 977,677,441$ (which is equivalent to 0.3% Iran's GDP) PPP respectively in 2022. The highest proportion of overall costs (52%) was attributable to indirect costs. Premature death accounted for 82.1% of this figure. While, the largest cost component within the direct costs category (57.2%) belonged to the professional and technical tariffs.

conclusionHemodialysis imposes a significant economic burden on Iranian society. In 2022, the annual cost of hemodialysis for Iran was approximately equivalent to 0.3% of the country's GDP. Preventive measures targeting the factors that predispose individuals to hemodialysis need to be seriously considered.

Indexed as

Cost of illnessEconomic burdenHemodialysisIranSocietal cost

Identifiers

PMID40522586
PMCPMC12168261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.